Advaxis CEO issues statement to shareholders regarding latest common stock transition Thomas A.

Our clinical trials and other key business activities are proceeding very well and are unaffected by this obvious change. Yours Sincerely, Thomas A. Moore Chairman/CEO.. Advaxis CEO issues statement to shareholders regarding latest common stock transition Thomas A. Moore, chairman and CEO of Advaxis, Inc., , the live, attenuated Listeria monocytogenes vaccine firm, has issued the following statement to shareholders relating to the recent transition to the OTCQB from the OTCBB: Dear Fellow Shareholders, Related StoriesNew vaccine candidate shows great promise at fighting respiratory syncytial virusResearchers reveal why malaria vaccine provides only moderate safety among vaccinated childrenResearch provides potential clients for new ways of develop HIV vaccineOver the last few days, achieving the Company’s stock estimate information has been incredibly difficult.Individuals were spending profit New York Town to do journal writing conferences, and in Mississippi, we couldn’t even obtain visitors to the clinics. Konkle-Parker said Mississippi offers about eight general public clinics to treat the majority of the 9,000 HIV patients in the constant state. The current economic crunch provides exacerbated the situation. Some continuing states, like Kentucky, have cut financing for HIV/Helps programs. The state have been contributing $250,000 a year ahead of 2007, but now minimal state money is defined for the AIDS Medication Assistance program aside, said Sigga Jagne, a scheduled program manager for the Kentucky Department of Health.